FindTrial
Sign In

GZR18

DRUG13 trials

Sponsors

Gan and Lee Pharmaceuticals, USA, Gan & Lee Pharmaceuticals.

Conditions

Diabetes Mellitus, Type 2ObesityObesity and OverweightObesity/OverweightObesity/Overweight in AdultOverweightOverweight and ObesityType 2 Diabetes

Phase 1

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT06256523
Gan and Lee Pharmaceuticals, USAType 2 Diabetes
Start: 2022-06-29End: 2023-09-28Updated: 2024-02-23
A Study of GZR18 Injection in Chinese Obese/Overweight Patients
CompletedNCT06256536
Gan and Lee Pharmaceuticals, USAObesity, Overweight
Start: 2022-07-14End: 2023-10-22Updated: 2024-02-23
A Phase I Study of GZR18 Injection in Healthy Subjects
CompletedNCT06548997
Gan and Lee Pharmaceuticals, USAOverweight and Obesity, Type 2 Diabetes
Start: 2021-12-02End: 2022-10-20Updated: 2024-08-14
A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
CompletedNCT06548945
Gan and Lee Pharmaceuticals, USAOverweight and Obesity
Start: 2023-04-25End: 2023-08-14Updated: 2024-08-14
A Study of GZR18 Tablet in Chinese Healthy Subjects
Active, not recruitingNCT06554054
Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 2
Start: 2024-04-01End: 2024-12-09Updated: 2024-08-14

Phase 2

A Study of GZR18 Injection in Obese/Overweight Patients
CompletedNCT06256562
Gan and Lee Pharmaceuticals, USAObesity, Overweight
Start: 2023-06-08End: 2024-06-05Updated: 2025-10-01
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
Active, not recruitingNCT06256549
Gan and Lee Pharmaceuticals, USAType 2 Diabetes
Start: 2023-08-09End: 2024-07-20Updated: 2024-02-23
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
CompletedNCT06737042
Gan and Lee Pharmaceuticals, USAObesity and Overweight
Start: 2025-02-24End: 2026-02-27Updated: 2026-07-16
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
Active, not recruitingNCT07055386
Gan & Lee Pharmaceuticals.Type 2 Diabetes Mellitus (T2DM)
Start: 2025-08-07End: 2027-01-31Target: 90Updated: 2025-11-21

Phase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
Active, not recruitingNCT06728124
Gan & Lee Pharmaceuticals.Obesity/Overweight
Start: 2024-12-30End: 2026-05-31Target: 630Updated: 2025-11-25
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Active, not recruitingNCT06777238
Gan & Lee Pharmaceuticals.Type 2 Diabetes Mellitus (T2DM)
Start: 2025-01-16End: 2027-03-10Updated: 2025-11-25
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Active, not recruitingNCT06778967
Gan & Lee Pharmaceuticals.Type 2 Diabetes Mellitus (T2DM)
Start: 2025-02-13End: 2026-12-11Target: 1100Updated: 2025-11-25
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
RecruitingNCT07150975
Gan & Lee Pharmaceuticals.Obesity/Overweight in Adult
Start: 2025-09-23End: 2027-06-30Target: 420Updated: 2025-11-25

Related Papers

Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
2026-06-19
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Signal Transduction and Targeted Therapy2026-02-27